不可切除局部晚期非小细胞肺癌同步放化疗后安罗替尼维持治疗的临床观察  

Efficacy of anlotinib maintenance therapy after concurrent chemoradiotherapy in unresectable locally advanced non-small cell lung cancer

作　　者：闫兰芳 武云[2] YAN Lanfang;WU Yun(Department of Oncology,Baotou Clinical School,Inner Mongolia Medical University,Baotou 014040,China)

机构地区：[1]内蒙古医科大学包头临床医学院肿瘤科,内蒙古包头014040 [2]包头市中心医院肿瘤科,014040

出　　处：《临床肿瘤学杂志》2022年第11期1020-1024,共5页Chinese Clinical Oncology

摘　　要：目的探讨不可切除的局部晚期非小细胞肺癌(NSCLC)同步放化疗后安罗替尼单药维持治疗的效果及安全性。方法收集2019年9月至2021年6月48例接受同步放化疗的不可切除局部晚期NSCLC患者,在同步放化疗结束1个月后进行疗效评价,获完全缓解、部分缓解或稳定的患者给予12 mg盐酸安罗替尼胶囊每日1次维持治疗,连续口服14天,21天为1个周期。观察无进展生存时间(PFS)和总生存时间(OS)以及不良反应的发生情况。结果截至2021年12月31日,48例患者中有41例达到PFS,全组中位PFS为15.6(95%CI:13.78~17.43)个月;48例患者中有10例达到OS终点,全组中位OS未达到,1、2年生存率分别为93.1%和73.5%。年龄、ECOG评分、同步放化疗疗效、CEA和Cyfra21-1水平与局部晚期NSCLC患者的PFS有关(P<0.05),性别、吸烟史、病理类型和临床分期与PFS无关(P>0.05)。全组主要不良反应为消化道反应、高血压、手足综合征、疲乏/无力等,均为1~2级。结论不可切除的局部晚期NSCLC患者经同步放化疗后行安罗替尼单药维持治疗,疗效及安全性良好,有望成为不可切除局部晚期NSCLC的有效方案。Objective To investigate the efficacy and safety of anlotinib single maintenance therapy after concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer(NSCLC).Methods Forty-eight patients with locally advanced unresectable NSCLC from September 2019 to June 2021 were enrolled in this study.Chest CT was reviewed one month after concurrent radiotherapy and chemotherapy,and the patients with complete remission,partial remission or stable disease were evaluated and started oral hydrochloride anlotinib capsules maintenance therapy.Anlotinib was given 12 mg orally once a day for two weeks and21 days was a cycle.Prognosis and side effect was observed.Results Till December 31,2021,41 of 48 patients had achieved the end point of progression-free survival(PFS)with a median PFS of 15.6(95%CI:13.78-17.43)months in 48 patients.Ten of the 48patients achieved the end point of overall survival(OS),and the median OS was not achieved.The 1-and 2-year survival rates were93.1%and 73.5%,respectively.Age,ECOG score,the efficacy of concurrent chemoradiotherapy,CEA and Cyfra21-1 level were related to PFS(P<0.05);but PFS was not related to gender,smoking,pathological type and TNM stage(P>0.05).The main side effects included gastrointestinal reactions,hypertension,hand-foot syndrome and fatigue/weakness.The side effects were all in grade 1-2.Conclusion Good efficacy and safety are observed in patients with unresectable locally advanced NSCLC treated with anlothinib maintenance therapy after concurrent radiotherapy and chemotherapy.The therapy is expected to become an effective scheme for unresectable locally advanced NSCLC.

关 键 词：非小细胞肺癌 同步放化疗 安罗替尼 维持治疗 

分 类 号：R734􀆰[医药卫生—肿瘤]